Having said that, unprofitable companies are risky because they could potentially burn through all their cash and become distressed. So, the natural question for Biomea Fusion (NASDAQ:BMEA) ...

Biomea Fusion, Inc. (NASDAQ:BMEA – Get Free Report) has been given an average recommendation of “Buy” by the twelve analysts that are covering the firm, Ratings reports. Two research analysts have ...

REDWOOD CITY, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery ...

Biomea Fusion, Inc. (NASDAQ:BMEA – Free Report) – Investment analysts at HC Wainwright lifted their FY2024 earnings estimates for shares of Biomea Fusion in a research note issued on Thursday ...

Biomea Fusion Inc. (NASDAQ:BMEA), a biotechnology company focused on developing innovative treatments for diabetes and obesity, finds itself at a critical juncture as it navigates regulatory ...

REDWOOD CITY, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical ...

Biomea Fusion Inc. (NASDAQ:BMEA), a biotechnology company focused on developing innovative treatments for diabetes and obesity, finds itself at a critical juncture as it navigates regulatory ...

Analyst Joseph Pantginis of H.C. Wainwright maintained a Buy rating on Biomea Fusion (BMEA – Research Report), retaining the price target ...

Detailed price information for Biomea Fusion Inc (BMEA-Q) from The Globe and Mail including charting and trades.

Zeit Aktuelle Nachrichten 05.11. Biomea Fusion's SWOT analysis: clinical hold clouds diabetes drug stock outlook 01.11. Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635 ...

Detailed price information for Biomea Fusion Inc (BMEA-Q) from The Globe and Mail including charting and trades.